- Home
- SCYX vs GBBK Comparison
SCYX vs GBBK Comparison
Compare SCYX & GBBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCYX
- GBBK
- Stock Information
- Founded
- SCYX 1999
- GBBK 2021
- Country
- SCYX United States
- GBBK United States
- Employees
- SCYX N/A
- GBBK N/A
- Industry
- SCYX Biotechnology: Pharmaceutical Preparations
- GBBK Blank Checks
- Sector
- SCYX Health Care
- GBBK Finance
- Exchange
- SCYX Nasdaq
- GBBK Nasdaq
- Market Cap
- SCYX 50.3M
- GBBK 60.1M
- IPO Year
- SCYX 2014
- GBBK 2022
- Fundamental
- Price
- SCYX $1.02
- GBBK $11.06
- Analyst Decision
- SCYX Buy
- GBBK
- Analyst Count
- SCYX 1
- GBBK 0
- Target Price
- SCYX N/A
- GBBK N/A
- AVG Volume (30 Days)
- SCYX 210.1K
- GBBK 163.0
- Earning Date
- SCYX 11-06-2024
- GBBK 01-01-0001
- Dividend Yield
- SCYX N/A
- GBBK N/A
- EPS Growth
- SCYX N/A
- GBBK N/A
- EPS
- SCYX N/A
- GBBK N/A
- Revenue
- SCYX $8,566,000.00
- GBBK N/A
- Revenue This Year
- SCYX N/A
- GBBK N/A
- Revenue Next Year
- SCYX $405.82
- GBBK N/A
- P/E Ratio
- SCYX N/A
- GBBK N/A
- Revenue Growth
- SCYX N/A
- GBBK N/A
- 52 Week Low
- SCYX $0.90
- GBBK $10.55
- 52 Week High
- SCYX $3.07
- GBBK $12.00
- Technical
- Relative Strength Index (RSI)
- SCYX 34.82
- GBBK 48.04
- Support Level
- SCYX $0.90
- GBBK $11.04
- Resistance Level
- SCYX $1.04
- GBBK $11.24
- Average True Range (ATR)
- SCYX 0.07
- GBBK 0.00
- MACD
- SCYX -0.01
- GBBK 0.01
- Stochastic Oscillator
- SCYX 34.10
- GBBK 14.29
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
About GBBK Global Blockchain Acquisition Corp.
Global Blockchain Acquisition Corp is a blank check company.